isoniazid (inH) and rifampicin (riF) continue to be first line anti-tuberculosis (TB) drugs. However, the use of these drugs is associated with hepatotoxicity. nuclear factor-κB (nF-κB) plays a crucial role in regulating immunity and inflammation. It has been reported that pyrrolidine dithiocarbamate (PdTc), an inhibitor of nF-κB, exerts a hepatoprotective effect on acute and chronic liver damage. The aim of the present study was to explore the inH/riF-induced protective effects and mechanisms of PdTc on liver injury. rats were intragastrically administered inH (50 mg/kg/day) and riF (50 mg/kg/day) daily for 28 days. PdTc (50 mg/kg/day) was intraperitoneally injected 2 h after the co-administration of inH and riF to compare liver biochemical indicators in the serum, histopathological damage, nF-κB activity, oxidative stress, hepatic mrna expression of tumor necrosis factor (TnF)-α, bile salt export pump (BSeP), and protein expression of BSeP. it was found that the inhibition of nF-κB activation by PdTc treatment markedly alleviated liver biochemical and histological injury, decreased oxidative stress and mrna levels of TnF-α, and prevented decreases in BSeP mrna and protein expression induced by the co-administration of inH and riF. collectively, the present data suggested that inH/riF-induced liver injury is dependent on the activation of nF-κB. PdTc exerted a therapeutic effect on inH/riF-induced liver injury by increasing BSeP expression, and exhibiting antioxidant and anti-inflammatory activities.